Fast‑moving regulation demands clear, compliant storytelling. Ground campaigns in approved labelling and use the FDA’s newly published CRLs to pre‑empt pitfalls and sharpen claims—across every channel. Read ICON’s lat...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
A multifaceted global approach to addressing antimicrobial resistance
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
This article is taken from European Biopharmaceutical Review October 2021, pages 70-73. Samedan Ltd
-
The bottom line: Clinical trials
Nuala Murphy contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
-
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
-
Has the pandemic enabled us to accelerate the pace of drug development?
Nuala Murphy, President Global Specialty Solutions, contributes to this Marvellous Medicine BBC4 podcast about accelerating the pace of drug development due to the pandemic.
-
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
-
What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer / BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
